We are live on ! Find out more

Rapid Micro Biosystems

RPID

Market cap $63.7M

1.27 USD

-0.04

3.05%

At close Updated Sep 8, 12:45 PM EDT

1 day

-3.05%

5 days

-16.99%

1 month

-25.73%

3 months

-36.18%

6 months

-69.76%

Year to date

-59.55%

1 year

-53.31%

5 years

-93.75%

10 years

-94.07%

About: Rapid Micro Biosystems Inc is a life sciences technology company. Its technology uses a sensitive camera and the natural autofluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The company develops, manufactures, markets, and sells Growth Direct systems (Systems), proprietary consumables, laboratory information management system (LIMS) connection, and other software and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices, and personal care products. Geographically, it generates maximum revenue from the United States, and the rest from Switzerland, Germany, Japan, and all other countries.

Employees: 171

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 18.2%

Neutral 63.6%

Negative 18.2%

Rapid Micro Biosystems to Participate in Upcoming Investor Conferences

LEXINGTON, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced plans to participate in the following upcoming investor conferences:

Rapid Micro Biosystems to Participate in Upcoming Investor Conferences

Zacks Investment Research

After Plunging 33.7% in 4 Weeks, Here's Why the Trend Might Reverse for Rapid Micro Biosystems (RPID)

Rapid Micro Biosystems (RPID) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

After Plunging 33.7% in 4 Weeks, Here's Why the Trend Might Reverse for Rapid Micro Biosystems (RPID)

Zacks Investment Research

Down 25.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Rapid Micro Biosystems (RPID)

The heavy selling pressure might have exhausted for Rapid Micro Biosystems (RPID) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down 25.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Rapid Micro Biosystems (RPID)

Zacks Investment Research

Rapid Micro Biosystems (RPID) Upgraded to Buy: What Does It Mean for the Stock?

Rapid Micro Biosystems (RPID) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Rapid Micro Biosystems (RPID) Upgraded to Buy: What Does It Mean for the Stock?

Rapid Micro Biosystems, Inc. (RPID) Q2 2026 Earnings Call Transcript

Rapid Micro Biosystems, Inc. (RPID) Q2 2026 Earnings Call Transcript

Rapid Micro Biosystems, Inc. (RPID) Q2 2026 Earnings Call Transcript

Rapid Micro Biosystems Q2 Earnings Call Highlights

Rapid Micro Biosystems NASDAQ: RPID reported second-quarter revenue of $8.1 million, up 11% from $7.3 million a year earlier and above the company's prior guidance, as consumable sales, service activity and recurring revenue increased.

Rapid Micro Biosystems Q2 Earnings Call Highlights

Zacks Investment Research

Rapid Micro Biosystems, Inc. (RPID) Reports Q2 Loss, Tops Revenue Estimates

Rapid Micro Biosystems, Inc. (RPID) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.27 per share a year ago.

Rapid Micro Biosystems, Inc. (RPID) Reports Q2 Loss, Tops Revenue Estimates

Rapid Micro Biosystems Reports Second Quarter 2026 Financial Results

Reports second quarter 2026 total revenue of $8.1 million , representing 11% growth compared to the second quarter of 2025 Achieved a significant milestone with the 200th Growth Direct system placed globally; placed four Growth Direct systems and completed nine validations in the second quarter 2026 Second quarter consumable revenue increased more than 20% year-over-year Second quarter recurring revenue increased 14% year-over-year; comprised 63% of total revenue Reports record second quarter total gross margin of 15% , an increase of 11 percentage points compared to the second quarter of 2025 Merck MilliporeSigma to host European Growth Direct Day in October 2026, supporting customer engagement, education, and commercial pipeline development across Europe Reaffirms full year 2026 total revenue guidance range of $37.0 million to $41.0 million, including 30 to 38 Growth Direct system placements Reaffirms full year 2026 gross margin percentage guidance of approximately 20%, with second half 2026 margins in the mid-20% range LEXINGTON, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the second quarter ended June 30, 2026.

Rapid Micro Biosystems Reports Second Quarter 2026 Financial Results

Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LEXINGTON, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced the grants on August 3, 2026, of 90,000 restricted stock units (“RSUs”) of the Company's Class A common stock (“Common Stock”) and a non-qualified stock option to purchase 170,000 shares of Common Stock (the “Option”), all as a material inducement to employment for a new employee. All such equity awards were made under the Company's Inducement Plan, as amended (the “Inducement Plan”) and were approved by a majority of the independent directors of the Board of Directors or a duly authorized committee thereof in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards are subject to the terms and conditions of the Inducement Plan, and the terms and conditions of the applicable stock option and RSU award agreements covering the grants.

Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rapid Micro Biosystems to Announce Second Quarter 2026 Financial Results on August 7, 2026

LEXINGTON, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release second quarter 2026 financial results prior to the market open on Friday, August 7, 2026.

Rapid Micro Biosystems to Announce Second Quarter 2026 Financial Results on August 7, 2026

See News Rankings

Price charts implemented using Lightweight Charts™